Lobbying disclosures · Lobbying report
BMY: second_quarter 2026 lobbying report
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.
Follow BMY- Became public
- Jul 20, 2026, 7:29 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 3:38 PM EST
Why this is connected
Legal-name match: BRISTOL-MYERS SQUIBB COMPANY is BRISTOL MYERS SQUIBB CO (https://www.sec.gov/Archives/edgar/data/14272/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $80,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/d31667f6-c34a-471e-ae31-021e614d3056/","filing_uuid":"d31667f6-c34a-471e-ae31-021e614d3056","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/d31667f6-c34a-471e-ae31-021e614d3056/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-20T19:29:18-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":60290,"url":"https://lda.gov/api/v1/clients/60290/","client_id":60290,"name":"BRISTOL-MYERS SQUIBB COMPANY","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker","new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie","new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":140826,"prefix":null,"prefix_display":null,"first_name":"TED","nickname":null,"middle_name":null,"last_name":"LEHMAN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant","new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":"Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140826,"prefix":null,"prefix_display":null,"first_name":"TED","nickname":null,"middle_name":null,"last_name":"LEHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BMY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 11, 2026$15K–$50K
Rep. Mike Kelly (R-PA-16)
Sold Bristol-Myers Squibb Company BMY
$15K–$50K · Traded May 7, 2026 · disclosed Jun 11, 2026 · Spouse
Got $3K from the company’s PAC - Feb 6, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Sold Bristol-Myers Squibb Company BMY
$15K–$50K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 15, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Dec 18, 2025 · disclosed Jan 15, 2026 · Joint
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Apr 28, 2025 · disclosed Jan 13, 2026 · filed 260 days later
Got $2K from the company’s PAC - Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 23, 2024 · disclosed Jan 13, 2026 · filed 447 days later
Got $2K from the company’s PAC
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.